



Published in final edited form as:

Science. 2020 April 10; 368(6487): 186–189. doi:10.1126/science.aau6481.

## Dendritic cell-derived hepcidin sequesters iron from the microbiota to promote mucosal healing

Nicholas J. Bessman<sup>1,2,3</sup>, Jacques R.R. Mathieu<sup>4,5,\*</sup>, Cyril Renassia<sup>4,5,\*</sup>, Lei Zhou<sup>1,2,3</sup>, Thomas C. Fung<sup>1,2,3</sup>, Keith C. Fernandez<sup>1,2,3</sup>, Christine Austin<sup>6</sup>, Jesper B. Moeller<sup>1,2,3,7</sup>, Sara Zumerle<sup>4,5</sup>, Sabine Louis<sup>4,5</sup>, Sophie Vaulont<sup>4,5</sup>, Nadim J. Ajami<sup>8</sup>, Harry Sokol<sup>9</sup>, Gregory G. Putzel<sup>1</sup>, Tara Arvedson<sup>10</sup>, Robbyn E. Sockolow<sup>11</sup>, Samira Lakhali-Littleon<sup>12</sup>, Suzanne M. Cloonan<sup>13,14</sup>, Manish Arora<sup>6</sup>, Carole Peyssonnaud<sup>4,5,\*\*</sup>, Gregory F. Sonnenberg<sup>1,2,3,\*\*</sup>

<sup>1</sup>Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY USA <sup>2</sup>Joan and Sanford I. Weill Department of Medicine, Division of Gastroenterology and Hepatology, Weill Cornell Medicine, Cornell University, New York, NY USA <sup>3</sup>Department of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, New York, NY USA <sup>4</sup>Université de Paris, INSERM U1016, Institut Cochin, CNRS UMR8104, 75014, Paris, France <sup>5</sup>Laboratory of Excellence GR-Ex, Paris, France <sup>6</sup>Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States. <sup>7</sup>Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark. <sup>8</sup>MD Anderson Cancer Center <sup>9</sup>Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Hôpital Saint Antoine, Service de Gastroenterologie, F-75012 Paris, France <sup>10</sup>Department of Oncology Research, Amgen Inc., Thousand Oaks, CA USA <sup>11</sup>Department of Pediatrics, Division of Gastroenterology and Nutrition, Weill Cornell Medicine, Cornell University, New York, NY, USA <sup>12</sup>Department of Physiology, Anatomy and Genetics, University of Oxford, OX1 3PT Oxford, United Kingdom <sup>13</sup>Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, Cornell University, New York, NY USA <sup>14</sup>Trinity College Dublin, Ireland.

### Abstract

Bleeding and altered iron distribution occur in multiple gastrointestinal diseases, but the significance or regulation of these changes remains unclear. Here we report that hepcidin, the master regulator of systemic iron homeostasis, is required for tissue repair in the intestine

\*\*Correspondence to: gfonnenberg@med.cornell.edu and carole.peyssonnaud@inserm.fr.

\*These authors contributed equally

**Author contributions:** N.J.B. and G.F.S. conceived the project. N.J.B., L.Z., T.C.F., K.C.F., J.B.M., J.R.R.M., C.R., S.L. and S.Z. performed experiments and analyzed data. S.V. and S.L.-L. provided mouse models and expertise. H.S. performed pathological analyses. T.A. provided tools and expertise. C.P. provided mouse models, designed and supervised experiments. N.J.A. and G.G.P. analyzed sequencing data. C.A. and M.A. performed and analyzed iron imaging. R.E.S. provided essential advice and guidance. S.M.C. provided guidance and iron measurements. N.J.B. and G.F.S. wrote the manuscript, with input from all the authors.

**Competing interests:** G.F.S. holds stock and is a member of an advisory board for Celsius Therapeutics Inc. T.A. is an employee of Amgen, Inc.. The other authors declare no competing interests.

**Data and materials availability:** All data necessary to understand and evaluate the conclusions of this paper are provided in the manuscript and supplementary materials. Microarray and 16S rRNA sequencing data are available from the GEO database with accession numbers GSE143869 and GSE139371. Floxed mice are available with a material transfer agreement.

following experimental damage. This effect was independent of hepatocyte-derived hepcidin or systemic iron levels. Rather, we identified that conventional dendritic cells (cDCs) are a source of hepcidin that is induced by microbial stimulation, prominent in the inflamed intestine of humans, and essential for tissue repair. Mechanistically, cDC-derived hepcidin acted on ferroportin-expressing phagocytes to promote local iron sequestration, which regulated the microbiota and subsequently facilitated intestinal repair. Collectively, these results identify a novel pathway whereby cDC-derived hepcidin promotes mucosal healing in the intestine via nutritional immunity.

### One Sentence Summary:

Dendritic cells produce an iron-regulatory factor that modulates the intestinal microbiota to promote mucosal healing.

---

Inflammatory bowel disease (IBD), colorectal cancer, and gastrointestinal infections cause tissue inflammation that drives bleeding, malabsorption, and diarrhea (1–3). As a result, patients frequently exhibit anemia that is difficult to treat, and bleeding introduces a new source of iron to the intestine (4, 5). Hepcidin is the master regulator of systemic iron homeostasis that is produced as a peptide hormone from the liver and promotes degradation of the cellular iron efflux transporter ferroportin (4, 6–10). Ferroportin is expressed on red pulp macrophages and the basolateral surface of duodenal enterocytes, where it facilitates iron recycling from senescent red blood cells and import of dietary iron, respectively (4, 6–10). Despite these advances, it remains unclear whether hepcidin impacts gastrointestinal health or disease.

To address this, we exposed wild-type (*Hamp*<sup>+/+</sup>) and hepcidin-deficient (*Hamp*<sup>-/-</sup>) mice to a model of intestinal tissue damage, inflammation, and repair by administering dextran sodium sulfate (DSS) in the drinking water. During DSS administration, both *Hamp*<sup>+/+</sup> and *Hamp*<sup>-/-</sup> mice exhibited similar weight loss (Fig. 1A), indicative of comparable inflammation and tissue damage. However, upon removal of DSS, *Hamp*<sup>-/-</sup> mice exhibited persistent weight loss, continued disruption of epithelial crypt architecture, and significantly reduced colon lengths relative to controls (Fig. 1A–C). Surprisingly, we observed significant DSS-dependent reductions in liver hepcidin expression, and reduced systemic hepcidin protein levels, relative to naïve controls (Fig. S1A, B). These data are consistent with negative feedback on hepcidin production due to anemia and erythropoiesis (11, 12). To test the role of hepatocyte-derived hepcidin, we bred mice with a floxed gene (*Hamp*<sup>F/F</sup>) to mice expressing Cre recombinase under the control of the albumin promoter, to generate *Hamp*<sup>liver</sup> mice that develop systemic iron overload comparable to hepcidin-deficient mice (13). Following exposure to DSS, *Hamp*<sup>liver</sup> mice and controls exhibited comparable recovery of body weight, tissue architecture, and colon length (Fig. 1D–F). Thus, hepcidin is essential for mucosal healing, but this occurs independent of hepatocyte expression and systemic iron regulation.

To interrogate the source(s) of hepcidin that promote mucosal healing, we analyzed tissues of naïve mice. We observed expression within the mesenteric lymph node (mLN) and lamina propria of the colon (cLP), which were maintained upon administration of DSS (Fig. 2A,

S1C, D). Previous in vitro studies indicated that macrophages produce hepcidin (14). Surprisingly, we observed that type 2 conventional dendritic cells (cDC2s), and not macrophages or type 1 cDCs (cDC1s), were the dominant myeloid source of hepcidin in the colon following DSS administration (Fig. 2B, C). Bacteria and bacteria-derived molecules were potent inducers of hepcidin expression in both bone marrow-derived DCs and sort-purified cDC2s (Fig. 2D and S2). Intestinal biopsies from Crohn's disease (CD) and ulcerative colitis (UC) patients revealed a significant increase in hepcidin expression as compared to healthy controls, and significant correlations with DC-associated genes (Fig. 2E, S3). Further, a recently described antibody for hepcidin (15), revealed that cDCs were major producers of hepcidin in the inflamed intestine of IBD patients (Fig. 2F, G). Thus, cDCs are a previously unappreciated source of hepcidin in the intestine of mice and humans that is induced by microbes.

We deleted hepcidin in cDCs by crossing  $CD11c^{Cre}$  mice with  $Hamp^{F/F}$  mice.  $Hamp^{CD11c}$  mice exhibited a selective loss of hepcidin expression in cDCs (Fig. 3A, S4A). DC development and systemic iron was comparable in  $Hamp^{CD11c}$  mice versus controls (Fig. S4B–D). Furthermore, lymphocyte, myeloid, and granulocyte responses were similar in  $Hamp^{CD11c}$  mice and controls during naïve conditions and following administration of DSS (Fig. S4E–F, S5). Global transcriptional profiling also revealed minimal changes in cDC subsets from  $Hamp^{CD11c}$  mice versus controls (Fig. S6). Thus, cDC-derived hepcidin does not impact immune responses in these contexts. By contrast,  $Hamp^{CD11c}$  mice exhibited significantly reduced body weight following removal of DSS, abnormal colon tissue architecture, and shortened colons relative to controls (Fig. 3B–D).  $Zbtb46^{Cre}$ -mediated deletion of hepcidin in cDCs resulted in a similar impairment of tissue repair relative to controls (Fig. S7). Thus, cDC-derived hepcidin is essential for mucosal healing.

We next profiled the colonic expression of ferroportin (*Slc40a1*) and observed high expression in epithelium, neutrophils, and macrophages (Fig. 3D). To determine whether these are the targets of hepcidin that facilitate mucosal healing, we utilized mice in which a hepcidin-resistant ferroportin variant, *Slc40a1<sup>C326Y</sup>*, is expressed from the endogenous locus after Cre-mediated recombination (Fig. S8A) and (16). The expression of *Slc40a1<sup>C326Y</sup>* in DCs or intestinal epithelial cells had no impact on mucosal healing (Fig. S8B–E). By contrast, *Slc40a1<sup>C326Y</sup>* expression in macrophages and neutrophils via  $LysM^{Cre}$  resulted in significantly reduced body weight, abnormal colonic tissue architecture, and shortened colons relative to controls and following removal of DSS (Fig. 3F–H). Consistent with post-translational regulation of ferroportin, DC-derived hepcidin did not impact *Slc40a1* or *Hmox1* mRNA levels in macrophages (Fig. S8F). Thus, ferroportin-expressing macrophages and/or neutrophils are a critical target for hepcidin-mediated mucosal healing.

To test whether this intestinal hepcidin-ferroportin axis regulates local iron distribution in the gut, we employed quantitative mass spectrometry imaging. Strikingly, iron levels within the cecal tissue of DSS-treated  $Hamp^{CD11c}$  mice were decreased versus controls (Fig. 4A, S9A, B). Consistent with this, non-heme iron levels were increased in the luminal content of  $Hamp^{CD11c}$  mice versus controls after DSS-induced damage, but not in naïve mice (Fig. 4B, S9C, D). This likely involves conversion of heme-bound iron from erythrocytes into non-heme-bound iron via heme oxygenase 1 in phagocytes (17), which would then efflux to

extracellular space through ferroportin unless regulated by hepcidin. Iron sequestration is a key component of nutritional immunity (4, 18, 19), so we examined whether cDC-derived hepcidin alters the microbiota. *Hamp*<sup>CD11c</sup> mice exhibited a significant shift in microbiota composition relative to littermate controls (Fig. 4C). Fecal microbiota transplantation (FMT) from *Hamp*<sup>CD11c</sup> mice to wild-type germ free recipients was sufficient to transfer impaired mucosal healing relative to controls (Fig. S10). *Catenibacteria* and *Bifidobacteria* were significantly different genera in *Hamp*<sup>CD11c</sup> mice relative to controls (Fig. S11A). Notably, *Bifidobacteria* supports epithelial barrier function, and dietary iron supplementation can suppress *Bifidobacteria* and exacerbate inflammation (20). We found *Bifidobacteria* expanded with restricted dietary iron, and oral administration of *Bifidobacteria* increased expression of intestinal tight junctions in wild-type mice and enhanced mucosal healing in *Hamp*<sup>CD11c</sup> mice (Fig. S11B–E). *Bifidobacteria* only partially restored normal mucosal healing, and the pathways by which DC-derived hepcidin promotes colonization with this microbe remains unclear. In addition, *Hamp*<sup>CD11c</sup> mice also exhibited significantly increased levels of tissue-infiltrating bacteria relative to controls following DSS exposure, and antibiotic treatment eliminated DSS-induced phenotypes (Fig. 4D, S12). To determine whether excess extracellular iron impairs healing in *Hamp*<sup>CD11c</sup> mice, we administered deferoxamine (DFO), which sequesters extracellular iron from bacteria by chelation (21). DFO treatment in DSS-exposed *Hamp*<sup>CD11c</sup> mice was sufficient to completely restore mucosal healing (Fig. 4E, F).

In summary, our results outline a model in which cDCs produce hepcidin in response to microbiota-derived signals, and subsequently limit iron release from intestinal phagocytes to limit tissue infiltration by the microbiota and thus promote mucosal healing (Fig. S13). This contrasts with liver-derived hepcidin, which acts as an endocrine hormone, is induced by inflammatory cytokines, and has the potential to protect against systemic infection (7, 22, 23). Although not observed in our models, it will be important to interrogate whether DC-derived hepcidin has the potential to directly impact the immune response or systemic iron homeostasis in other contexts. Furthermore, our results indicate that hepcidin mimetics could be a beneficial therapeutic strategy in the context of FMT or gastrointestinal diseases where mucosal healing is an emerging therapeutic goal.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments:

We thank members of the Sonnenberg Laboratory for discussions and critical reading of the manuscript, the Epigenomics Core of Weill Cornell Medicine, and Samah Mozumder and Kihwan Kim for technical assistance.

**Funding:** Research in the Sonnenberg Laboratory is supported by the National Institutes of Health (NIH) fellowship to N.J.B. (F32AI124517), a Crohn's and Colitis Foundation fellowship to L.Z. (608975) and the following to G.F.S.: NIH (R01AI143842, R01AI123368, R01AI145989, R21CA249274 and U01AI095608), the NIAID Mucosal Immunology Studies Team (MIST), the Searle Scholars Program, the American Asthma Foundation Scholar Award, an Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund, a Wade F.B. Thompson/Cancer Research Institute (CRI) CLIP Investigator grant, the Meyer Cancer Center Collaborative Research Initiative, and Linda and Glenn Greenberg, and the Roberts Institute for Research in IBD (JRI). G.F.S. is a CRI Lloyd J. Old STAR. Funding support also included the European Research Council (FP7/2011-2015 #261296), the "Fondation pour la Recherche Médicale" (DEQ20160334903), the

Laboratory of Excellence GR-Ex (ANR-11-LABX-0051), a labex GR-Ex fellowship (to J.R.R.M. and S.L.), the French National Research Agency (ANR-11-IDEX-0005-02), the “Fondation ARC pour la recherche sur le cancer” to S.Z., the NIH (PP30ES023515 and 1U2CES030859 to C.A. and M.A.; and R00HL125899 to S.M.C.), and the Science Foundation Ireland (FRL4862 to S.M.C.). The JRI IBD Live Cell Bank is supported by the JRI, Jill Roberts Center for IBD, Cure for IBD, the Rosanne H. Silberman Foundation and Weill Cornell Medicine Division of Pediatric Gastroenterology and Nutrition.

## References and Notes:

1. Karin M, Lawrence T, Nizet V, Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. *Cell* 124, 823–835 (2006). [PubMed: 16497591]
2. Kaser A, Zeissig S, Blumberg RS, Inflammatory Bowel Disease. *Annual Review of Immunology* 28, 573–621 (2010).
3. Khor B, Gardet A, Xavier RJ, Genetics and pathogenesis of inflammatory bowel disease. *Nature* 474, 307–317 (2011). [PubMed: 21677747]
4. Muckenthaler MU, Rivella S, Hentze MW, Galy B, A Red Carpet for Iron Metabolism. *Cell* 168, 344–361 (2017). [PubMed: 28129536]
5. Weiss G, Goodnough LT, Anemia of Chronic Disease. *New England Journal of Medicine* 352, 1011–1023 (2005). [PubMed: 15758012]
6. Donovan A et al., The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. *Cell metabolism* 1, 191–200 (2005). [PubMed: 16054062]
7. Drakesmith H, Nemeth E, Ganz T, Ironing out Ferroportin. *Cell metabolism* 22, 777–787 (2015). [PubMed: 26437604]
8. Fung E et al., High-throughput screening of small molecules identifies hepcidin antagonists. *Molecular pharmacology* 83, 681–690 (2013). [PubMed: 23292796]
9. Ganz T, Nemeth E, Hepcidin and Disorders of Iron Metabolism. *Annual Review of Medicine* 62, 347–360 (2011).
10. Nemeth E et al., Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. *Science (New York, N.Y.)* 306, 2090–2093 (2004).
11. Pasricha SR, McHugh K, Drakesmith H, Regulation of Hepcidin by Erythropoiesis: The Story So Far. *Annual review of nutrition* 36, 417–434 (2016).
12. Shanmugam NK, Trebicka E, Fu LL, Shi HN, Cherayil BJ, Intestinal inflammation modulates expression of the iron-regulating hormone hepcidin depending on erythropoietic activity and the commensal microbiota. *J Immunol* 193, 1398–1407 (2014). [PubMed: 24973448]
13. Zumerle S et al., Targeted disruption of hepcidin in the liver recapitulates the hemochromatotic phenotype. *Blood* 123, 3646–3650 (2014). [PubMed: 24646470]
14. Peyssonnaud C et al., TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. *Blood* 107, 3727–3732 (2006). [PubMed: 16391018]
15. Sasu BJ et al., Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. *Blood* 115, 3616–3624 (2010). [PubMed: 20053755]
16. Lakhali-Littleton S et al., An essential cell-autonomous role for hepcidin in cardiac iron homeostasis. *eLife* 5, (2016).
17. Kayama H et al., Heme ameliorates dextran sodium sulfate-induced colitis through providing intestinal macrophages with noninflammatory profiles. *Proceedings of the National Academy of Sciences*, (2018).
18. Lopez CA, Skaar EP, The Impact of Dietary Transition Metals on Host-Bacterial Interactions. *Cell host & microbe* 23, 737–748 (2018). [PubMed: 29902439]
19. Drakesmith H, Prentice AM, Hepcidin and the iron-infection axis. *Science (New York, N.Y.)* 338, 768–772 (2012).
20. Sarkar A, Mandal S, Bifidobacteria—Insight into clinical outcomes and mechanisms of its probiotic action. *Microbiological Research* 192, 159–171 (2016). [PubMed: 27664734]
21. Hider RC, Hoffbrand AV, The Role of Deferiprone in Iron Chelation. *New England Journal of Medicine* 379, 2140–2150 (2018). [PubMed: 30485781]


22. Casu C, Nemeth E, Rivella S, Hepcidin agonists as therapeutic tools. *Blood* 131, 1790–1794 (2018). [PubMed: 29523504]
23. Michels K, Nemeth E, Ganz T, Mehrad B, Hepcidin and Host Defense against Infectious Diseases. *PLOS Pathogens* 11, e1004998 (2015). [PubMed: 26291319]

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript



**Fig. 1. Extra-hepatic hepcidin promotes mucosal healing.**

Mice were given DSS for 7 days, and disease and recovery was monitored by weight loss (A), H&E staining of distal colon (B), and colon shortening (C) at day 12. Mice were given DSS for 9 days and recovery was monitored by weight loss (D), H&E staining of the distal colon (E), and colon shortening (F). All scale bars are 200  $\mu$ m. Data in (A-C, E) are representative of  $n=3-5$  mice per group replicated in two or more independent experiments, and data in D and F are pooled from two independent experiments with  $n=3-4$ . Data are shown as the mean  $\pm$  SEM. Statistics comparing groups used unpaired two-tailed Student's  $t$ -test (\*\*: $p<0.01$ ; \*\*\*: $p<0.001$ ; \*\*\*\*: $p<0.0001$ ). In (A) and (D), weights at sacrifice, normalized to starting weight, were analyzed by unpaired two-tailed Student's  $t$ -test.



**Fig. 2. Conventional dendritic cells are a source of hepcidin in the inflamed intestine.** Hepcidin expression was analyzed by qPCR in naïve mouse tissue (A). Mice were provided DSS for 7 days, colon lamina propria myeloid cells were sorted as noted (B), and hepcidin expression was analyzed by qPCR (C). cDC2s sorted from spleen were stimulated and hepcidin expression was analyzed (D). Hepcidin expression was quantified from intestinal biopsies of humans (E). Lamina propria cells from the inflamed ileum of pediatric CD patients were analyzed for hepcidin protein (F-G). For (A, C, and D), representative data with n=3–5 per group are shown, and data were replicated in at least two independent trials. In (E), n=5 for the healthy group and n=21 for the UC and CD groups. In (F), representative histograms are shown. In (G), four independent patients were tested and all data was pooled. All data are shown as mean ± SEM. In (A, D, and E) data were analyzed by unpaired two-tailed Student’s *t*-test; in (C), data were analyzed by the Mann–Whitney *U* test; in (G), data




were analyzed by one-way ANOVA with Tukey's multiple comparisons test (\*:p<0.05; \*\*:p<0.01; \*\*\*:p<0.001).

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript



**Fig. 3. Dendritic cell-derived hepcidin acts on ferroportin-expressing phagocytes to facilitate mucosal healing.**

Hepcidin expression was determined by qPCR in mice exposed to DSS for 7 days (A). Mice were given DSS for 8 days, and recovery was monitored by weight change (B), H&E staining of distal colon (C), and colon shortening (D). Sort-purified cells from the naïve mouse colon were analyzed for *Slc40a1* expression by qPCR (E). Mice were given DSS for 7 days and recovery was monitored by weight change (F), H&E staining of distal colon (G), and colon shortening (H). All scale bars are 200  $\mu$ m. All data are shown as mean  $\pm$  SEM. Data in (D) and (H) were analyzed by unpaired two-tailed Student's *t*-test. In (B) and (F), weights at sacrifice, normalized to starting weight, were analyzed by unpaired two-tailed Student's *t*-test. For all statistical tests, \*:p<0.05; \*\*:p<0.01; \*\*\*:p<0.001; \*\*\*\*:p<0.0001. Data in (A-D) are representative of at least two independent experiments with n=3–5 per group. Data in (F) and (H) are pooled from, and data in (J) is representative of, three independent experiments with n=1–3 per group.



**Fig. 4. Dendritic cell-derived hepcidin sequesters iron to shape the intestinal microbiota.** Mice were exposed DSS for 7 days. Whole ceca tissues were analyzed for iron levels by quantitative mass spectrometry imaging (A), and iron levels were quantified in colon lumen contents (B). Fecal microbiota were analyzed by 16S rRNA gene sequencing and principal coordinate analysis (C). Mice were exposed to DSS for 7 days and bacterial CFU were quantified from colon tissue homogenates (D). Mice were given DSS in drinking water for 7 days and treated daily with either PBS vehicle or DFO from day 0 through day 11. DSS-induced disease and recovery was monitored by weight loss (E) and H&E staining of distal colon (F). In (A), two independent experiments with n=1–5 per group were performed and representative data is shown. Data in (B) and (E) are pooled data from two independent experiments, each with n=3–5 per group. Data in (C) and (D) are representative of two independent experiments with n=5 per group. In (B) and (D), groups were compared using unpaired two-tailed Student's *t*-test. In (C), p-value was determined using a PERMANOVA test. In (E) weights at sacrifice, normalized to starting weight, were analyzed by one-way ANOVA using Tukey's multiple comparisons. In (F), representative data are shown from two independent experiments with n=3–5 per group, and scale bars are 200 μm. For all statistical tests, (\*:p<0.05; \*\*:p<0.01).